Eksempler på brug af Darifenacin på Engelsk og deres oversættelser til Dansk
{-}
-
Medicine
-
Colloquial
-
Official
-
Financial
-
Ecclesiastic
-
Official/political
-
Computer
Each tablet contains 7.5 mg darifenacin.
Darifenacin is metabolised by CYP3A4 and CYP2D6.
Darifenacen metaboliseres af CYP3A4 og CYP2D6.How should I use Dariten OD(Darifenacin)?
Hvordan skal jeg bruge Dariten OD(Darifenacin)?Lactation Darifenacin is excreted into the milk of rats.
Amning Darifenacin udskilles i mælk hos rotter.What are the side effects of Dariten OD(Darifenacin)?
Hvad er bivirkninger af Dariten OD(Darifenacin)?The active substance is darifenacin as hydrobromide.
Aktivt stof: darifenacin som hydrobromid.Darilong(Darifenacin) may cause side effects in some users.
Darilong(Darifenacin) kan give bivirkninger i nogle brugere.How should I use Darilong(Darifenacin Hydrobromide)?
Hvordan skal jeg bruge Darilong(Darifenacin Hydrobromide)?Darifenacin hydrobromide is a substance which reduces the activity of an overactive bladder.
Darifenacin hydrobromid er et stof som nedsætter aktiviteten af en overaktiv blære.Each tablet contains 7.5 mg darifenacin as hydrobromide.
Hver tablet indeholder 7, 5 mg darifenacin som hydrobromid.Only a small percentage of the excreted dose was unchanged darifenacin 3.
Kun en lille procentdel af den udskilte mængde var uomdannet darifenacin 3.The active substance in EMSELEX, darifenacin, is an anticholinergic medicine.
Det aktive stof i EMSELEX, darifenacin, er et antikolinergt middel.Doubling the darifenacin dose from 7.5 mg to 15 mg result in a 150% increase in steady-state exposure.
Fordobling af darifenacindosis fra 7, 5 mg til 15 mg resulterer i 150% øgning ved steady state eksponering.What are the side effects of Darilong(Darifenacin Hydrobromide)?
Hvad er bivirkningerne af Darilong(Darifenacin Hydrobromide)?Darifenacin undergoes significant metabolism by cytochrome CYP3A4 and CYP2D6 in the liver and by CYP3A4 in the gut wall.
Darifenacin undergår signifikant metabolisme af cytochrom CYP3A4 og CYP2D6 i leveren og i tarmvæggen af CYP3A4.Pregnancy There are no studies of darifenacin in pregnant women.
Graviditet Der er ikke udført forsøg med darifenacin hos gravide kvinder.Food had no effect on darifenacin pharmacokinetics during multiple-dose administration of prolonged-release tablets.
Fødeindtagelse har ingen indvirkning på darifenacins farmakokinetik ved kontinuerlig indtagelse af depottabletterne.Therefore, inhibitors of these enzymes may increase darifenacin exposure.
Hæmmere af disse enzymer kan derfor øge darifenacins eksponering.However, protein binding of darifenacin was affected by moderate hepatic impairment.
Proteinbinding af darifenacin blev dog påvirket af moderat leverinsufficiens.The increase in digoxin exposure could be caused by competition between darifenacin and digoxin for P-glycoprotein.
Den øgede digoxin eksponering kan skyldes konkurrence mellem darifenacin og digoxin om P- glycoprotein.Distribution Darifenacin is a lipophilic base and is 98% bound to plasma proteins primarily to alpha-1-acid- glycoprotein.
Fordeling Darifenacin er en lipofil base, 98% er bundet til plasmaproteiner primært alfa- 1- syre- glycoprotein.In subjects who are poor metabolisers, darifenacin exposure increased approximately 10-fold.
Hos patienter, som har beskeden metabolisme, øges eksponeringen af darifenacin cirka 10 gange.The interaction with midazolam lacks clinical relevance butis indicative of a slight CYP3A4 inhibition by darifenacin.
Interaktionen med midazolam mangler klinisk relevans, mener en indikation for en let CYP3A4 hæmning af darifenacin.CYP3A4 substrates Darifenacin treatment resulted in a modest increase in the exposure of the CYP3A4 substrate midazolam.
CYP3A4 substrater Behandling med darifenacin resulterede i en lettere øget eksponering af CYP3A4 substratet midazolam.Digoxin Therapeutic drug monitoring for digoxin should be performed when initiating and ending darifenacin treatment as well as changing the darifenacin dose.
Digoxin Monitoring af digoxin bør foretages, når behandling med darifenacin initieres og afsluttes samt ved ændring af Effects of darifenacin on other medicinal products CYP2D6 substrates Darifenacin is a moderate inhibitor of the enzyme CYP2D6.
Effekt af darifenacin på andre lægemidler CYP2D6 substrater Darifenacin er en moderat hæmmer af enzymet CYP2D6.EMSELEX are white(7.5 mg) or light peach(15 mg)round prolonged-release tablets that contain the active substance darifenacin prolonged-release means that darifenacin is released slowly from the tablet over a few hours.
EMSELEX er hvide(7, 5 mg) eller let ferskenfarvede(15 mg)runde depottabletter, der indeholder det aktive stof darifenacin en depottablet betyder, at darifenacin afgives langsomt fra tabletten i løbet af nogle få timer.The effects of darifenacin on the metabolism of CYP2D6 substrates are mainly clinically relevant for CYP2D6 substrates which are individually dose titrated.
Effekten af darifenacin på metabolismen af CYP2D6 substrater er hovedsagelig klinisk relevant for CYP2D6 substrater, som dosistitreres individuelt.CYP2D6 poor metabolisers The metabolism of darifenacin in CYP2D6 poor metabolisers is principally mediated by CYP3A4.
Patienter med beskeden CYP2D6 metabolisme Principielt er metabolismen af darifenacin hos patienter med beskeden CYP2D6 metabolisme medieret af CYP3A4.Therapeutic and supra-therapeutic doses of darifenacin resulted in no increase in QT/ QTc interval prolongation from baseline compared to placebo at maximum darifenacin exposure.
Terapeutiske og supra- terapeutiske doser af darifenacin resulterede ikke i nogen øget forlængelse af QT/ QTc interval fra basisniveau ved maksimal darifenacin eksponering, sammenlignet med placebo.
